Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

By G. Bakris, V. Fonseca, R. Katholi, J. McGill, F. Messerli, R. Phillips, P. Raskin, J. Wright, R. Oakes, M. Lukas and 2 more. Journal of the American Medical Association (JAMA), 2004

781 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/9eab8b586b24729534d3c4a32e8b924b74f829dd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Philippe van de Borne
2. S. Laurent
3. E. Schiffrin
4. S. Grundy
5. H. S. Boudier
6. B. K. Pedersen
7. B. Saltin

In Endocrinology, Diabetes and Metabolism

1. Philippe van de Borne
2. S. Grundy

Citations in the corpus

• The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “As the metabolic syndrome can often be considered as a ‘prediabetic’ state, agents such as RAS blockers and calcium antagonists are preferred, since they potentially improve—or at least do not worsen—insulin sensitivity, while beta-blockers (with the exception of vasodilating beta-blockers) [407–409”
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. (2007, neutral): “Exenatide is indicated for combination therapy with a secretagogue (sulfonylurea) (36), metformin (37), a secretagogue (sulfonylurea) plus metformin (38), and a thiazolidinedione with or without metformin.”
• Metabolic syndrome update. (2016, background): “indicated, appear to be preferable for patients with metabolic syndrome [111].”
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, background): “Some of the limitations of traditional beta-blockers do not appear to be shared by some of the vasodilating beta-blockers, such as celiprolol, carvedilol and nebivolol—more widely used today—which reduce central pulse pressure and aortic stiffness better than atenolol or metoprolol [404–406] and aff”